Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06846281 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06846281 · ClinicalTrials.gov record · last posted 2026-08-26

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Name: Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — clinical trial record (NCT06846281)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorNovartis Pharmaceuticals

Started2025-06-23

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

Protocol amendment history 6 changes detected by DataLookout

2026-08-27

Enrollment increased: 360 → 400 participants

2026-08-11

Trial sites expanded: 120 → 128 locations

2026-06-27

Trial sites expanded: 106 → 120 locations

2026-05-13

Trial sites expanded: 99 → 102 locations

2026-04-30

Trial sites expanded: 95 → 99 locations

2026-03-31

Trial sites expanded: 86 → 94 locations

Trial Details

NCT Number	NCT06846281
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Relapsing Multiple Sclerosis
Enrollment	400 participants
Start Date	2025-06-23
Primary Completion	2029-07-25 (estimated)
Study Completion	2031-06-25 (estimated)
Updated on ClinicalTrials.gov	2026-08-26